PROFESSIONALS
Broad-Spectrum Activity with QUIXIN®
QUIXIN® is indicated in patients aged 1 year and older for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
Aerobic Gram-Positive Microorganisms
Corynebacterium species*
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Streptococcus (Groups C/F)
Streptococcus (Group G)
Viridans group streptococci
Aerobic Gram-Negative Microorganisms
Acinetobacter lwoffii*
Haemophilus influenzae
Serratia marcescens*
*Efficacy for this organism was studied in fewer than 10 infections.
In vitro minimal inhibitory concentrations (MICs) of 2 µg/mL or less (systemic susceptible breakpoint) against most (≥90%) strains of the following ocular pathogens:
Aerobic Gram-Positive Microorganisms
Enterococcus faecalis
Staphylococcus saprophyticus
Streptococcus agalactiae
Streptococcus pyogenes
Aerobic Gram-Negative Microorganisms
Acinetobacter anitratus
Acinetobacter baumannii
Citrobacter diversus
Citrobacter freundii
Enterobacter aerogenes
Enterobacter agglomerans
Enterobacter cloacae
Escherichia coli
Haemophilus parainfluenzae
Klebsiella oxytoca
Klebsiella pneumoniae
Legionella pneumophila
Moraxella catarrhalis
Morganella morganii
Neisseria gonorrhoeae
Proteus mirabilis
Proteus vulgaris
Providencia rettgeri
Providencia stuartii
Pseudomonas aeruginosa
Pseudomonas fluorescens
The clinical significance in ophthalmic infections is unknown. The safety and effectiveness of levofloxacin in treating ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials.
